Altamira Therapeutics announces nanoparticle-based delivery of circular RNA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2024
0mins
Nanoparticle-based Delivery Platform: Altamira Therapeutics has successfully tested its nanoparticle delivery platform for circular mRNA, showing improved protein expression compared to linear mRNA in vitro.
New Offerings and Patent Application: The company has filed a provisional patent application and will offer its platform under the CycloPhore label to biotech and pharma companies, expanding its services beyond siRNA and mRNA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
